# AZD4547 & Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients Who Have Progressed on NSAIs (RADICAL)

> **NCT01791985** · PHASE1,PHASE2 · COMPLETED · sponsor: **Imperial College London** · enrollment: 52 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** AZD4547 / anastrozole or letrozole

## Key facts

- **NCT ID:** NCT01791985
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2016-11
- **Final completion:** 2018-12
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2022-08-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01791985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01791985, "AZD4547 & Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients Who Have Progressed on NSAIs (RADICAL)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01791985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*